

## **WEB-RADR Newsletter, September 2019: issue 1**

We are delighted to present the first WEB-RADR newsletter to adopters of the WEB-RADR platform. The WEB-RADR Team would like to build a user community and keep adopters up-to-date with the latest developments with the platform. The WEB-RADR platform currently includes the Yellow Card, HALMED, Bijwerking, UAE RADR and Med Safety applications (apps). The Med Safety app has been launched in Burkina Faso, Zambia, Ghana and Armenia.

The newsletter will be distributed on a quarterly basis and provide updated on current progress and exciting upcoming work.

This first issue provides updates on recent improvements and future enhancements. These improvements and fixes have been made to improve the stability of the app and enhance user experience.

### **1. Personalisation**

Logged in users can create 'watch lists' of medicines of interest and receive personalised news and alerts specific to the medicines on the watch lists. Medicinal products can be added to the watch list by selecting the 'add to watch list' button within the products tab. Selected products will then automatically appear in the watch list tab. Products can be removed from the watch list by unselecting the product's tick box.

### **2. Submitted reports**

Logged in users can view previously submitted reports and any pending reports.

### **3. Guest use without log in**

Users are able browse the app without having to log in. Users are also able to submit a report whilst being a guest user (no log in required). However, log in is advised so that a record of the report(s) is visible for the user within their account.

### **4. Offline capability**

Users continue to be able to create reports whilst offline. The reports can be saved and submitted when users regain Internet connectivity.

### **5. Display**

The logo and text displays have been updated for easier navigation and translations made more accurate.

### **6. Touch ID**

Touch ID has been implemented for use with iOS devices.

### **Coming soon:**

1. The WEB-RADR apps are undergoing significant enhancements as a result of delivery through WEB-RADR 2 – a project to expand the reach and capability of WEB-RADR. The WEB-RADR 2 project is funded through Innovative Medicines Initiative (IMI) as part of call IMI2 Call 11. Further information can be found on the project website: <https://web-radr.eu/web-radr2/>.
2. An enhanced back-end system called the adverse drug reaction (ADR) Hub has been created. This provides more flexibility for country administrators to configure the WEB-RADR apps themselves such as uploading translations and amending app branding. In the coming months, the ADR Hub will enable country

administrators to edit the layout of reporting forms by adding or removing questions to suit local settings.

3. The ADR Hub will allow country administrators to manually add and manage news items displayed in the app. News items can be created de novo and publishing dates set in advance.
4. The WEB-RADR app has been adapted by AbbVie as part of the WEB-RADR 2 project. The app is to be called 'e-PV': the name was chosen in a company-wide competition in AbbVie where national PV teams put in their suggestions. The app is now branded and undergoing extensive validation as is required by international data standards. Once the User acceptance testing is complete, the app will be piloted for use in AbbVie South Africa. We will be measuring baseline and pilot data on case quality, volume and time taken to process an adverse event.

